P89.07 A Large-Scale Survey of IDH1/2 Mutation in Chinese Patients with NSCLC

M. Jin,J. Zhang,H. Zhu,S. Chen,Z. Liu,J. Li,S. Hao,J. Luo,D. Wang,T. Ma,L. Dong,L. Teng,J. Liu,X. Li

DOI: https://doi.org/10.1016/j.jtho.2021.01.1272

IF: 20.121

2021-01-01

Journal of Thoracic Oncology

Abstract:Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes, which catalyzes isocitrate to α-ketoglutarate (αKG). Mutations of IDH family were identified in multiple tumor types, including sarcomas, hematologic malignancies, brain cancer and bile duct carcinoma. And the IDH mutation proteins confer neomorphic activity, resulting in the conversion of αKG to D-2-hydroxyglutarate (2-HG) and epigenetic dysregulation via accumulation of 2-HG. Increasing preclinical studies and clinical trials indicating that IDH mutation inhibitors could reverse epigenetic dysregulation and induce cellular differentiation by decrease intracellular 2-HG accumulation.